Phase 2 study for people with Lupus

Not yet recruiting Phase 2

Sources: ClinicalTrials.gov Checked: 11 October 2026 Not medical advice

This trial at a glance

Status Not yet recruiting
Phase Phase 2
Sponsor Myeloid Therapeutics
Registry number NCT07778446
Started 24 August 2026 Today 16 October 2026 Estimated completion 1 December 2028

Where this trial is running

Trial sites and the status recorded for each
SiteCityState or countryStatus at this site
Linear Advanced Clinical Trial Centre, Ground Floor, B Block, Queen Elizabeth II Medical Centre, Hospital Avenue Nedlands WA Status not stated

voxsanity.com.au · trial sites from public registries · registry record synced 11 October 2026 · not medical advice

Who can join

Age 18 Years and over
Sex Anyone, regardless of sex
Healthy volunteers Not accepted
Enrolment target 34

The official eligibility criteria

Registry text, reproduced exactly. These are the words the trial's sponsor published on ClinicalTrials.gov. They have not been edited, shortened or rewritten, and they are written for researchers rather than for patients.

Inclusion Criteria:

* Age 18 years or older.

* Diagnosis of active, refractory systemic lupus erythematosus, systemic sclerosis, or idiopathic inflammatory myopathy meeting established classification criteria, with inadequate response or intolerance to standard therapy.

* Adequate renal, hepatic, cardiac, and pulmonary function per protocol-defined criteria.

* Participants of reproductive potential must agree to use protocol-specified contraception during the study and for a defined period after dosing.

* Females of childbearing potential must have a negative pregnancy test before treatment.

* Must be willing and able to attend study visits and follow all study requirements.

Exclusion Criteria:

* Clinical suitability for a less burdensome and/or approved therapeutic approach, as judged by the Investigator,

* Any medical condition or laboratory abnormality that, in the Investigator's judgment, would place the participant at unacceptable risk or confound interpretation of study data,

* Prior Cluster of differentiation 19 (CD19)-directed, cell, or gene therapy,

* History of bone marrow/ hematopoietic stem cell or solid organ transplantation,

* Active or inadequately treated infection, including Human immunodeficiency (HIV), hepatitis B or C, or tuberculosis,

* Pregnancy or lactation.

Dates on the record

Started 24 August 2026
Estimated completion 1 December 2028
Registry last updated 21 August 2026
Checked by Voxsanity 11 October 2026

Results, publications and the official record

Sources and dates

  • ClinicalTrials.gov – the record this page reformats
  • ClinicalTrials.gov processing date: 21 August 2026.
  • This page last checked by Voxsanity: 11 October 2026.

Voxsanity reformats data from public registries into this layout. It does not edit, interpret or add to what the registry published.

Not medical advice.

Individual trial records are refreshed on a rolling basis rather than all at once, so a record may be up to several weeks old. Each trial page and trial card shows the date its own record was last synced. Where a record has lagged, its status, sites and enrolment can differ from the current registry state in either direction, so check the registry link on the trial page before acting on them.

Letter for your doctor

A one-page summary of this trial to print or email to your GP. It carries the registry's own record of the trial and its eligibility criteria, and nothing Voxsanity has written about whether it suits you.